Vical Incorporated: Vical Reports Second Quarter 2014 Financial Results and …

Vical Incorporated: Vical Reports Second Quarter 2014 Financial Results and …

The Company's Phase 1/2 trial of its therapeutic vaccine designed to reduce shedding and reduce severity and recurrence of genital lesions in HSV-2 positive subjects is on schedule. The first two dose escalation cohorts are fully enrolled and dosed.

9
Like
Save

Comments

Comments are disabled for this post.